Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Novo Nordisk has acquired the global rights to United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn.

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Indeed, the stakes are high. Novo Nordisk recently suffered a setback with CagriSema, its next-generation injectable drug in testing to treat both obesity and type 2 diabetes. The drug hit its ...

STORY: Since launching its popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

its next-generation weight loss drug CagriSema; and a move to diversify into rare diseases, with several data readouts expected this year. In 2025, Novo Nordisk is guiding for annual sales growth ...